Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update

- Acquisition adds GV104, a clinical-stage opioid countermeasure with a 505(b)(2) pathway and an active investigational new drug application, and GV023, an oral formulation of an approved anti-TNF antibody -- FDA has stated in writing that …